Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.

The American journal of gastroenterology - 1 Jul 2011

Yuen Man-Fung, Seto Wai-Kay, Fung James, Wong Danny Ka-Ho, Yuen John Chi-Hang, Lai Ching-Lung

Abstract excerpt

OBJECTIVES: We aimed to determine the antiviral potency, viral resistance rate, and clinical safety of 3-year continuous entecavir treatment. METHODS: We determined the cumulative rates of undetectable hepatitis B virus DNA (HBV DNA) levels (< 12 IU/ml), hepatitis B e antigen (HBeAg) seroconversion, alanine aminotransferase (ALT) normalization, and entecavir signature mutations (using the sensitive line probe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Drug Resistance, Viral

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Source

Identifiers

PMID: 21364549
DOI: 10.1038/ajg.2011.45

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.PMID 21364549Read ↗

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.Semantic proximity Read ↗

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Semantic proximity Read ↗

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.Semantic proximity Read ↗

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.Semantic proximity Read ↗

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #Semantic proximity Read ↗

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.Semantic proximity Read ↗

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.Semantic proximity Read ↗

Treatment of chronic hepatitis B: Evolution over two decadesSemantic proximity Read ↗

Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.Semantic proximity Read ↗

[Entecavir].Semantic proximity Read ↗

Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.Semantic proximity Read ↗

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.